Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA6 | P23280 | 2/20 | 0.38 |
| ▸ | CA7 | P43166 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CASP2 | P42575 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20985200 | 1.00 | ESR1 (0.56) | ESR1LMNATDP1CA12CA6 | |
| SCHEMBL38044 | 0.95 | — | — | |
| SCHEMBL8906125 | 0.86 | ESR1 (0.60) | ESR1LMNATDP1CA12CA6 | |
| SCHEMBL4983850 | 0.84 | ESR1 (0.67) | ESR1LMNATDP1CA12CA6 | |
| SCHEMBL12846992 | 0.83 | — | — | |
| SCHEMBL11228775 | 0.83 | ESR1 (0.74) | ESR1LMNATDP1CA12CA6 | |
| SCHEMBL7524242 | 0.83 | ESR1 (0.74) | ESR1LMNATDP1CA12CA6 | |
| SCHEMBL12427551 | 0.83 | — | — | |
| SCHEMBL4449112 | 0.81 | — | — | |
| SCHEMBL3360937 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12529013-B2 | Injectivity improvement with thioalcohols | BAKER HUGHES OILFIELD OPERATIONS LLC (US) | 2026-01-20 | — | — | US | claimed |
| EP-4594443-A1 | INJECTIVITY IMPROVEMENT WITH THIOALCOHOLS | Baker Hughes Oilfield Operations LLC (US) | 2025-08-06 | — | — | EP | claimed |
| WO-2024108008-A1 | INJECTIVITY IMPROVEMENT WITH THIOALCOHOLS | BAKER HUGHES OILFIELD OPERATIONS LLC (US) | 2024-05-23 | — | — | WO | claimed |
| EP-4031642-A1 | METAL REMOVAL FROM FLUIDS | Baker Hughes Holdings LLC (US) | 2022-07-27 | — | — | EP | claimed |
| US-11326109-B2 | Metal removal from glycol fluids | BAKER HUGHES HOLDINGS LLC (US) | 2022-05-10 | — | — | US | claimed |
| US-20210246376-A1 | METAL REMOVAL FROM GLYCOL FLUIDS | BAKER HUGHES, A GE COMPANY, LLC (US) | 2021-08-12 | — | — | US | claimed |
| WO-2021055135-A1 | METAL REMOVAL FROM FLUIDS | BAKER HUGHES, A GE COMPANY, LLC (US) | 2021-03-25 | — | — | WO | claimed |
| US-20080138309-A1 | Use Of Aminodithiol As A Reducing Agent For Hair Perming | L'OREAL S.A. (FR) | 2008-06-12 | — | — | US | claimed |
| US-20060189567-A1 | Compound having affinity with calcified tissue | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2006-08-24 | — | — | US | claimed |
| EP-1609797-A1 | COMPOUND HAVING AFFINITY WITH CALCIFIED TISSUE | Nihon Medi-Physics Co., Ltd. (JP) | 2005-12-28 | — | — | EP | claimed |
| US-6660863-B2 | Reacting an cycloheptatriene nitrile compound with nortropane compound | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2003-12-09 | — | — | US | claimed |
| US-20030109708-A1 | Process for synthesizing anhydroecgonine derivative | NIHON MEDI-PHYSICS CO., LTD. | 2003-06-12 | — | — | US | claimed |
| US-20010020096-A1 | Process for synthesizing anhydroecgonine derivative | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2001-09-06 | — | — | US | claimed |
| EP-1127887-A1 | Process for synthesizing anhydroecgonine derivative | NIHON MEDI-PHYSICS Co., Ltd. (JP) | 2001-08-29 | — | — | EP | claimed |
| US-6127530-A | Method for the reduction of oxygenated compounds of rhenium or technetium | NYCOMED AMERSHAM SORIN S.R.L. (IT) | 2000-10-03 | — | — | US | claimed |
| US-20260117145-A1 | INJECTIVITY IMPROVEMENT WITH THIOALCOHOLS | BAKER HUGHES OILFIELD OPERATIONS LLC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2026-03-26 | — | — | US | disclosed |
| EP-0279417-A2 | Ester-substituted diaminedithiols and radiolabeled complexes thereof | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1988-08-24 | — | — | EP | disclosed |
| US-4272632-A | BIS-MERCAPTOALKYL-ETHYLENE(PROPYENE-)DIAMINE | POLAROID CORPORATION (US) | 1981-06-09 | — | — | US | disclosed |
| US-4251617-A | THIO-POLYAMINES, DIFFUSION TRANSFER PHOTOGRAPHY | POLAROID CORPORATION (US) | 1981-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | KLK3, FOLH1, PSMA1 | ESR1 1300/4885LMNA 1421/4885TDP1 3533/4885 |
| US-20080138309-A1 | Use Of Aminodithiol As A Reducing Agent For Hair Perming | AASDHPPT, BHMT2, ALAD | ESR1 4869/4885LMNA 2070/4885TDP1 1377/4885 |
| US-20260117145-A1 | INJECTIVITY IMPROVEMENT WITH THIOALCOHOLS | GLO1, SORD, ALAD | ESR1 3476/4885LMNA 4793/4885TDP1 2854/4885 |
| US-20060189567-A1 | Compound having affinity with calcified tissue | SLC7A1, MBNL1, SHBG | ESR1 1605/4885LMNA 1384/4885TDP1 4878/4885 |
| US-20030109708-A1 | Process for synthesizing anhydroecgonine derivative | CES2, NPR1, OPRL1 | ESR1 2793/4885LMNA 3660/4885TDP1 2245/4885 |
| US-12529013-B2 | Injectivity improvement with thioalcohols | GLO1, PIGS, OGA | ESR1 3189/4885LMNA 4599/4885TDP1 3020/4885 |
| US-20010020096-A1 | Process for synthesizing anhydroecgonine derivative | CES2, NPR1, OPRL1 | ESR1 2793/4885LMNA 3660/4885TDP1 2245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.